Pulse Biosciences Appoints Paul LaViolette as CEO to Drive Medical Innovation

Pulse Biosciences Appoints New Leadership to Propel Medical Innovations

Pulse Biosciences, Inc. (Nasdaq: PLSE) takes a significant step forward by appointing Paul A. LaViolette as its new Chief Executive Officer. Previously serving as Co-Chairman of the Board, LaViolette brings a wealth of experience from the medical technology sector, including 15 years at Boston Scientific Corporation and influential roles at CR Bard and Medtronic. Robert W. Duggan, Co-Chairman of the Board, endorses LaViolette’s leadership capabilities, noting his extensive background in managing large-scale operations and investing in innovative healthcare startups. LaViolette’s qualifications, including his MBA from Boston College and a Bachelor's in psychology, position him as a strong leader to guide Pulse Biosciences towards its strategic goals.

LaViolette is particularly enthusiastic about the potential of the company’s proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology. He highlights that this innovative approach has the capacity to transform patient care and the broader healthcare landscape. Under LaViolette's leadership, Pulse Biosciences is actively developing its nano-PFA Cardiac Surgical System and nano-PFA 360° Cardiac Catheter, currently engaged in first-in-human feasibility studies in Europe. Additionally, the company is piloting its FDA-cleared nsPFA Percutaneous Electrode Systems in select U.S. locations, indicating a robust commitment to advancing its technological capabilities in the field.

As Pulse Biosciences prepares to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference, LaViolette’s appointment is viewed as a pivotal moment in the company’s trajectory. His extensive network and experience are expected to enhance the company’s market presence, paving the way for the adoption of its groundbreaking therapies. With LaViolette at the helm, Pulse Biosciences aims to solidify its position as a leader in the medical technology sector, fostering innovation that could significantly improve patient outcomes.

In addition to this leadership change, Pulse Biosciences continues to focus on its research and development initiatives, showcasing its commitment to advancing healthcare technology. The company's innovative approach to treatment reflects a broader trend in the medical industry, where novel technologies are increasingly prioritized to enhance surgical precision and patient care.

With LaViolette steering the company towards its ambitious goals, Pulse Biosciences is poised to make substantial contributions to the medical technology landscape, leveraging its unique methodologies to benefit healthcare providers and patients alike.